VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO Breast 2020 | Personalizing immunotherapy beyond PDL1 expression

Marleen Kok, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, discusses personalizing immunotherapy beyond PD-L1 expression. Specifically discussed is the IMpassion130 trial (NCT02425891), neoadjuvant data and tumor mutational burden. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter